Takeda's phase 3 aurora study provides evidence of maribavir's clinically meaningful and durable effect in cytomegalovirus (cmv) infection in hematopoietic stem cell transplant patients, despite missing primary endpoint

Osaka, japan & cambridge, mass.--( business wire )--takeda (tse:4502/nyse:tak) today announced that in the aurora trial, a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cmv infection in hematopoietic stem cell transplant (hsct) recipients, maribavir demonstrated clinically meaningful efficacy in confirmed cmv viremia clearance*, but did not meet its primary endpoint of non-inferiority vs. valganciclovir (maribavir 69.6% [190/273] vs. valganciclovir 77.4% [212/274]; adjusted difference, -7.7%; 95% ci: -14.98, -0.36), based on the prespecified non-inferiority margin of 7%. the primary endpoint was defined as the proportion of patients who achieved confirmed cmv viremia clearance (plasma cmv dna
TAK Ratings Summary
TAK Quant Ranking